Salix Pharmaceuticals Company Profile (NASDAQ:SLXP)

About Salix Pharmaceuticals

Salix Pharmaceuticals logoSalix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SLXP
  • CUSIP: 79543510
Key Metrics:
  • Previous Close: $169.00
  • 50 Day Moving Average: $173
  • 200 Day Moving Average: $133
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 18.78
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to Salix Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Salix Pharmaceuticals (NASDAQ:SLXP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Salix Pharmaceuticals (NASDAQ:SLXP)
DateFirmActionRatingPrice TargetDetails
3/18/2015Jefferies GroupDowngradeBuy -> Hold$149.00 -> $173.00View Rating Details
3/16/2015MizuhoBoost Price TargetNeutral$158.00 -> $173.00View Rating Details
2/24/2015Cantor FitzgeraldDowngradeBuy -> Hold$151.00 -> $158.00View Rating Details
2/23/2015Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
2/23/2015Piper Jaffray Cos.DowngradeOverweight -> Neutral$160.00 -> $158.00View Rating Details
2/12/2015Sterne Agee CRTDowngradeBuy -> NeutralView Rating Details
12/18/2014Deutsche Bank AGReiterated RatingHold$107.00View Rating Details
12/18/2014Goldman Sachs Group Inc.Reiterated RatingHOLD$111.00View Rating Details
12/18/2014Credit Suisse Group AGBoost Price TargetNeutral$111.00 -> $121.00View Rating Details
12/17/2014Canaccord GenuityBoost Price TargetBuy$117.00 -> $147.00View Rating Details
11/7/2014Roth CapitalDowngradeBuy -> Neutral$155.00 -> $95.00View Rating Details
11/7/2014Stifel NicolausDowngradeBuy -> Hold$185.00View Rating Details
11/7/2014William BlairDowngradeOutperform -> Market Perform$184.00 -> $89.00View Rating Details
(Data available from 10/23/2014 forward)


Earnings History for Salix Pharmaceuticals (NASDAQ:SLXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/2/2015Q414($0.29)($2.61)$187.97 million$13.00 millionViewN/AView Earnings Details
11/6/2014Q314$1.56$1.53$394.00 million$354.70 millionViewN/AView Earnings Details
8/7/2014Q214$1.69$1.59$397.06 million$382.00 millionViewListenView Earnings Details
5/8/2014Q114$0.91$1.05$372.91 million$384.00 millionViewListenView Earnings Details
2/27/2014Q413$0.93$1.06$247.29 million$257.60 millionViewListenView Earnings Details
11/7/2013Q313$0.86$0.89$239.70 million$238.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.81$0.87$226.34 million$235.40 millionViewListenView Earnings Details
5/9/2013Q1 2013$0.67$0.63$205.94 million$202.60 millionViewListenView Earnings Details
2/28/2013Q4 2012$0.78$0.81$199.41 million$198.17 millionViewN/AView Earnings Details
11/7/2012Q312$0.69$0.95$187.23 million$185.13 millionViewN/AView Earnings Details
8/8/2012$0.54$0.79ViewN/AView Earnings Details
5/7/2012$0.56$0.67ViewN/AView Earnings Details
11/8/2011$0.60$0.77ViewN/AView Earnings Details
8/8/2011$0.44$0.32ViewN/AView Earnings Details
5/5/2011$0.17$0.34ViewN/AView Earnings Details
2/28/2011$0.49$0.66ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Salix Pharmaceuticals (NASDAQ:SLXP)
Current Year EPS Consensus Estimate: $4 EPS
Next Year EPS Consensus Estimate: $9 EPS


Dividend History for Salix Pharmaceuticals (NASDAQ:SLXP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Salix Pharmaceuticals (NASDAQ:SLXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/6/2015Timothy J CreechInsiderSell4,600$157.67$725,282.00View SEC Filing  
3/6/2015William P ForbesEVPSell20,000$157.96$3,159,200.00View SEC Filing  
11/12/2014William P ForbesEVPSell11,079$95.05$1,053,058.95View SEC Filing  
6/26/2014Carolyn J LoganCEOSell53,057$123.38$6,546,172.66View SEC Filing  
4/22/2014Alonzo Thomas DDirectorSell11,530$110.89$1,278,561.70View SEC Filing  
1/10/2014Alonzo Thomas DDirectorSell12,050$91.83$1,106,551.50View SEC Filing  
1/9/2014Adam DerbyshireCFOSell30,001$91.48$2,744,491.48View SEC Filing  
1/8/2014William ForbesEVPSell8,000$90.06$720,480.00View SEC Filing  
1/7/2014Rick ScruggsEVPSell8,463$88.31$747,367.53View SEC Filing  
1/7/2014William KeaneDirectorSell22,500$88.31$1,986,975.00View SEC Filing  
7/24/2013William P ForbesEVPSell12,000$70.93$851,160.00View SEC Filing  
4/10/2013William P ForbesEVPSell8,673$49.37$428,186.01View SEC Filing  
12/26/2012Adam C DerbyshireCFOSell60,000$41.44$2,486,400.00View SEC Filing  
11/13/2012Mark A SirgoDirectorSell3,450$40.53$139,828.50View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Salix Pharmaceuticals (NASDAQ:SLXP)
News IconBroker Roundup For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - The De Soto Edge (NASDAQ:SLXP) - October 19 at 1:29 PM logoValeant’s Investment Here Could Improve Future Profit Margins (NASDAQ:SLXP) - October 18 at 12:43 PM
News IconControversy Over Lead Poisoning Drug Pricing - PharmaLive (press release) (subscription) (NASDAQ:SLXP) - October 12 at 7:17 PM
News IconBroker Changes For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - NewsDen (NASDAQ:SLXP) - October 11 at 1:29 PM
News IconSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Updated Broker Price Targets - The De Soto Edge (NASDAQ:SLXP) - October 9 at 6:35 PM
News IconLatest Analyst Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - The De Soto Edge (NASDAQ:SLXP) - September 29 at 7:15 PM
News IconValeant Pharmaceuticals Intl Inc: VRX Stock to Regain Value? - Profit Confidential (NASDAQ:SLXP) - September 27 at 7:15 PM logoValeant’s Strategies for Its Dermatology, Gastroenterology Drugs (NASDAQ:SLXP) - September 20 at 12:07 PM
News IconValeant Stock: Many Are Bullish on Valeant Pharmaceuticals Intl Inc - Profit Confidential (NASDAQ:SLXP) - September 19 at 11:55 AM logoValeant: Are the Salix and Dermatology Portfolios Recovering? (NASDAQ:SLXP) - September 14 at 11:43 AM logoNew Broker Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ ... - FTSE News (NASDAQ:SLXP) - July 26 at 10:51 AM logoValeant gets new approval for legacy Salix drug (NASDAQ:SLXP) - July 20 at 1:50 PM logoValeant's Drug Approvals May Save the Day (NASDAQ:SLXP) - July 20 at 12:30 PM logoValeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles (NASDAQ:SLXP) - July 20 at 9:21 AM logoNext Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Fiscal Standard (NASDAQ:SLXP) - July 17 at 11:30 AM logoSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Updated Price Targets - FTSE News (NASDAQ:SLXP) - June 28 at 7:19 PM logoSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Current Analyst Ratings - Fiscal Standard (NASDAQ:SLXP) - June 24 at 7:32 PM logoHow Much Is Valeant Pharmaceuticals Really Worth? (NASDAQ:SLXP) - June 17 at 2:41 PM
News IconPfizer Drug Prices Rise By 8.8% Average - PharmaLive (press release) (subscription) (NASDAQ:SLXP) - June 11 at 10:25 AM logoDoctors Who Prescribed Salix Drugs Ate Well (NASDAQ:SLXP) - June 10 at 3:43 PM logoDetails of kickbacks and fraud emerge in Valeant's Salix unit settlement (NASDAQ:SLXP) - June 10 at 11:55 AM logoValeant (VRX) Stock Slides on $54 Million Settlement (NASDAQ:SLXP) - June 10 at 8:56 AM logoValeant pays $54 million to settle U.S. kickback, fraud claims (NASDAQ:SLXP) - June 9 at 5:45 PM logoValeant pays $54 mln to settle U.S. kickback, fraud claims (NASDAQ:SLXP) - June 9 at 5:43 PM logoValeant Unit Settles Claims of Pushing Drugs With Pricey Dinners (NASDAQ:SLXP) - June 9 at 4:38 PM logoU.S. joins whistleblower lawsuit against Valeant's Salix unit (NASDAQ:SLXP) - June 9 at 3:58 PM logoValeant pays $47M to settle 2013 DOJ investigation into legacy Salix drugs (NASDAQ:SLXP) - June 8 at 12:35 PM logoBiotech: 2 Attractive Buyout Targets For Under $7 A Share - Seeking Alpha (NASDAQ:SLXP) - May 26 at 1:11 PM
News IconSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:SLXP) - May 16 at 10:42 AM
News IconSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Latest Broker Views - Risers & Fallers (NASDAQ:SLXP) - April 22 at 6:24 PM logoBiomerica - Growing Revenue, Solid Balance Sheet And Potentially Significant Upside From IBS Test - Seeking Alpha (NASDAQ:SLXP) - April 19 at 6:31 PM
News IconRecently Changed Price Targets On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers (NASDAQ:SLXP) - April 12 at 11:30 PM
News IconSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Latest Broker Coverage - Risers & Fallers (NASDAQ:SLXP) - April 8 at 6:29 PM
News IconSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Analyst Review - Risers & Fallers (NASDAQ:SLXP) - April 7 at 6:36 PM logoReport: Valeant cutting Addyi sales force (NASDAQ:SLXP) - April 5 at 4:30 PM
News IconLatest Analyst Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Share Trading News (NASDAQ:SLXP) - April 4 at 6:17 PM
News IconNext Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Share Trading News (NASDAQ:SLXP) - April 3 at 5:47 PM
News IconThis Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Share Trading News (NASDAQ:SLXP) - March 28 at 10:53 PM
News IconSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Broker Updates - Risers & Fallers (NASDAQ:SLXP) - March 23 at 11:02 PM logoNew Broker Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - FTSE News (NASDAQ:SLXP) - March 22 at 5:58 PM logoAtlantic Healthcare closes $24 million financing with founders of Salix Pharmaceuticals and Clinigen Group, and LDC - Business Wire (press release) (NASDAQ:SLXP) - March 21 at 8:59 AM logoBMO Still Believes Valeant Is Undervalued - Benzinga (NASDAQ:SLXP) - March 17 at 6:12 PM logoRevenue from Salix drug lower than Valeant expected (NASDAQ:SLXP) - March 15 at 4:55 PM logoValeant missed huge on its 'billion dollar' savior drug — that should raise a big red flag (NASDAQ:SLXP) - March 15 at 12:36 PM logoHow Salix/Sprout affected Valeant's earnings (NASDAQ:SLXP) - March 15 at 10:25 AM
News IconSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Updated Price Targets - Share Trading News (NASDAQ:SLXP) - March 7 at 11:08 PM logoValeant Says It's Under Investigation by SEC, Shares Plunge (NASDAQ:SLXP) - February 29 at 3:39 PM logoWhere Salix fits in Valeant’s earnings restatement (NASDAQ:SLXP) - February 23 at 5:35 PM logoValeant Has Risk Of New Undisclosed SEC Probe, Report Says (NASDAQ:SLXP) - February 23 at 9:07 AM
News IconPrice Target Update On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers (NASDAQ:SLXP) - February 18 at 9:44 AM


Salix Pharmaceuticals (NASDAQ:SLXP) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff